![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The net proceeds will be used to support the HOPE® 1 formal FDA clinical program. Zelira has established a SPV to conduct FDA clinical trials for Zelira’s proprietary and patent protected HOPE 1.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Hope 1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Forman Investment Trust
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Financing January 08, 2024
Details:
The net proceeds will be used to support the HOPE® 1 formal FDA clinical program. Zelira has established a SPV to conduct FDA clinical trials for Zelira’s proprietary and patent protected HOPE 1.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Hope 1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Forman Investment Trust
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Financing August 17, 2023
Details:
23 chronic insomnia patients treated with ZLT-101, Zelira's proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index.
Lead Product(s): ZLT-101
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
Details:
Zelira Therapeutics is assisting Parkinson’s Foundation in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD.
Lead Product(s): Cannabinoid-based Product
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Recipient: Parkinson’s Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 28, 2020